Better together – therapeutic area results
August 7, 2019
August 7, 2019
We surveyed 4,000 patients across four countries with one of three specific conditions in order to better understand how patients use, engage with and value services from patient organizations in comparison to those from pharma companies and other healthcare players. The results lead to three key findings:
Here is where we found some unique differences by condition:
In general, patients are more willing to share detailed information about the daily impact of their condition with patient organizations (56 percent) than they are pharma (49 percent).
Migraine patients were most willing to share information about the impact of their condition with pharma companies (53 percent) but CLL patients were the least willing (44 percent).
Of all patients surveyed, 61 percent are completely or very satisfied with the services they receive from patient organizations.
67%
of CLL patients are satisfied overall with the level of support they get to manage their condition across all organizations they engage with.
ONLY57%
of migraine patients are satisfied with the level of emotional, financial, and other daily support they get to manage their condition.
Less than half of patients (47 percent) said pharma companies understood their emotional, financial and other needs related to their condition—ranking the lowest across all three disease states (49 percent in migraine, 47 percent in arthritis, and 44 percent in CLL).
While patients are engaging the most with patient organizations by digital means (online + email), 72 percent of CLL patients are attending events hosted by patient organizations and calling to talk to a representative over 80 percent of the time.
Pharma companies must innovate and collaborate with patient organizations to better understand patients’ individual needs. This will allow them to create a seamless experience for patients and enable delivery of better services, helping patients recover in new ways.